Volume 12 Supplement 1

Abstracts of the 13th Annual SCMR Scientific Sessions - 2010

Open Access

19F MRS assessment of siRNA delivery to vascular cells via perfluorocarbon nanoparticles

  • Jacob W Myerson1,
  • Megan M Kaneda1,
  • Gregory M Lanza1 and
  • Samuel A Wickline1
Journal of Cardiovascular Magnetic Resonance201012(Suppl 1):P103


Published: 21 January 2010


RNA interference mediated by the introduction of exogenous siRNAs has been a powerful tool for the modulation of gene expression. The ability to track siRNA delivery would be advantageous for future in vivo studies.


To design a synthetic vehicle to serve as both an siRNA delivery agent and an imaging agent, perfluorocarbon nanoparticles (PFC-NP) were loaded with the cationic lipid 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP) in the lipid monolayer to form transfection complexes with siRNA to the VCAM-1 gene. siRNA loading onto nanoparticles was measured via PAGE gel. Mouse 2F2B endothelial cells were incubated with transfection complexes (PFC-NP/siRNA) for 4 h. 19F MR spectroscopy was performed at 11.7 T to determine the number of NP bound to each cell. mRNA levels were measured 48 h after transfection to determine knockdown.


The loading conditions used in this experiment resulted in 645 siRNA molecules per nanoparticle. Incubation with 2F2B cells led to a roughly linear increase in bound nanoparticles over the range of concentrations tested. In one condition which resulted in a 72% reduction in VCAM-1 mRNA levels, 19F spectroscopy data reported 5563 particles per cell.


For future in vivo studies, a trackable delivery agent would aid in the determination of localization of siRNA delivery to specific tissues. To this end, we have developed a nanoparticle which is able to deliver siRNA to mouse endothelial cells and whose signal can be detected by 19F MR spectroscopy and imaging.

Authors’ Affiliations

Washington University in Saint Louis


© Myerson et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.